Drivers of Broad-Spectrum Antibiotic Overuse across Diverse Hospital Contexts-A Qualitative Study of Prescribers in the UK, Sri Lanka and South Africa.
South Africa
Sri Lanka
UK
antibacterial agents
antimicrobial stewardship
decision making
hospitals
physicians
qualitative methods
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
19 Jan 2021
19 Jan 2021
Historique:
received:
17
12
2020
revised:
08
01
2021
accepted:
18
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
23
1
2021
Statut:
epublish
Résumé
Antimicrobial stewardship programs focus on reducing overuse of broad-spectrum antibiotics (BSAs), primarily through interventions to change prescribing behavior. This study aims to identify multi-level influences on BSA overuse across diverse high and low income, and public and private, healthcare contexts. Semi-structured interviews were conducted with 46 prescribers from hospitals in the UK, Sri Lanka, and South Africa, including public and private providers. Interviews explored decision making about prescribing BSAs, drivers of the use of BSAs, and benefits of BSAs to various stakeholders, and were analyzed using a constant comparative approach. Analysis identified drivers of BSA overuse at the individual, social and structural levels. Structural drivers of overuse varied significantly across contexts and included: system-level factors generating tensions with stewardship goals; limited material resources within hospitals; and patient poverty, lack of infrastructure and resources in local communities. Antimicrobial stewardship needs to encompass efforts to reduce the reliance on BSAs as a solution to context-specific structural conditions.
Identifiants
pubmed: 33477994
pii: antibiotics10010094
doi: 10.3390/antibiotics10010094
pmc: PMC7835907
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Economic and Social Research Council
ID : ES/P004784/1
Références
Ann Intern Med. 2019 Aug 6;171(3):153-163
pubmed: 31284301
PLoS One. 2019 Jan 16;14(1):e0209847
pubmed: 30650099
Clin Microbiol Infect. 2019 Feb;25(2):163-168
pubmed: 30195471
Bioethics. 2019 Sep;33(7):756-765
pubmed: 31264232
BMJ Open. 2017 Apr 8;7(4):e012974
pubmed: 28391232
Qual Health Res. 2020 Sep;30(11):1684-1696
pubmed: 32458726
BMC Health Serv Res. 2008 Jun 06;8:123
pubmed: 18538009
Future Microbiol. 2016 Aug;11:1057-71
pubmed: 27501941
BMJ Qual Saf. 2019 Sep;28(9):758-761
pubmed: 31018985
J Antimicrob Chemother. 2019 Sep 1;74(9):2803-2809
pubmed: 31169902
Aust Health Rev. 2015 Jun;39(3):315-322
pubmed: 25556967
J Hosp Infect. 2019 Apr;101(4):428-439
pubmed: 30099092
Antimicrob Resist Infect Control. 2016 Dec 20;5:58
pubmed: 28031814
J Antimicrob Chemother. 2012 Jul;67 Suppl 1:i51-63
pubmed: 22855879
Glob Health Action. 2019;12(1):1599560
pubmed: 31294679
Int J Infect Dis. 2020 Jul;96:621-629
pubmed: 32505875
BMJ Glob Health. 2019 Aug 15;4(4):e001590
pubmed: 31497315
Clin Microbiol Infect. 2017 Oct;23(10):752-760
pubmed: 28341492
Infect Control Hosp Epidemiol. 2015 Sep;36(9):1065-72
pubmed: 26078017
Antimicrob Resist Infect Control. 2019 Apr 15;8:63
pubmed: 31011417
Clin Infect Dis. 2013 Jul;57(2):188-96
pubmed: 23572483
Drugs. 1998 Mar;55(3):323-30
pubmed: 9530540
Palgrave Commun. 2019 May 22;5:
pubmed: 31157116
Soc Sci Med. 2003 Aug;57(4):733-44
pubmed: 12821020
MMWR Morb Mortal Wkly Rep. 2014 Mar 7;63(9):194-200
pubmed: 24598596
Sci Rep. 2020 Nov 2;10(1):18782
pubmed: 33139823
Surg Infect (Larchmt). 2020 Aug;21(6):478-494
pubmed: 31816263
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Int J Antimicrob Agents. 2015 Mar;45(3):203-12
pubmed: 25630430
Clin Microbiol Infect. 2017 Nov;23(11):812-818
pubmed: 28712667
Arch Intern Med. 2003 Apr 28;163(8):972-8
pubmed: 12719208